Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies, the U.S.-based biotech discovers using its AI-driven gene-editing platform, in a deal worth up to $555 million.
AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related disorders in exchange for upfront and milestone payments to Algen.
Read more | REUTERS